{"id":"twinrix-adult","safety":{"commonSideEffects":[{"rate":"40–50","effect":"Injection site soreness or pain"},{"rate":"10–15","effect":"Fatigue"},{"rate":"10–15","effect":"Headache"},{"rate":"5–10","effect":"Myalgia"},{"rate":"1–5","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Twinrix contains inactivated hepatitis A virus and recombinant hepatitis B surface antigen (HBsAg) that trigger adaptive immune responses. Upon vaccination, the body produces specific antibodies and cellular immunity against both pathogens, providing protection against infection with either virus. The combination vaccine simplifies immunization schedules by delivering both vaccines in a single formulation.","oneSentence":"Twinrix is a combined vaccine that stimulates the immune system to produce antibodies against both hepatitis A and hepatitis B viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:28.021Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis A infection in adults ≥18 years"},{"name":"Prevention of hepatitis B infection in adults ≥18 years"}]},"trialDetails":[{"nctId":"NCT00875485","phase":"PHASE4","title":"Evaluation of Antibody Persistence & Immune Memory in Subjects Vaccinated During Adolescence With Twinrix™","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-01","conditions":"Hepatitis B, Hepatitis A","enrollment":210},{"nctId":"NCT00289744","phase":"PHASE3","title":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-02-16","conditions":"Hepatitis B, Hepatitis A","enrollment":178},{"nctId":"NCT00197184","phase":"PHASE3","title":"Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11-01","conditions":"Hepatitis B, Hepatitis A","enrollment":276},{"nctId":"NCT00289770","phase":"PHASE3","title":"Long-term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Mth Schedule in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-01","conditions":"Hepatitis B, Hepatitis A","enrollment":50},{"nctId":"NCT00465816","phase":"PHASE3","title":"Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-11","conditions":"Infections, Meningococcal","enrollment":611},{"nctId":"NCT00289718","phase":"PHASE3","title":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11-01","conditions":"Hepatitis B, Hepatitis A","enrollment":51},{"nctId":"NCT00197119","phase":"PHASE3","title":"Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-05","conditions":"Hepatitis B, Hepatitis A","enrollment":244},{"nctId":"NCT00197171","phase":"PHASE3","title":"Long Term F/U Studies at Y5&6 to Demonstrate the Equivalence of 2 Vaccination Schedules of Combined Hepatitis A & B Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-09","conditions":"Hepatitis B, Hepatitis A","enrollment":143}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combined hepatitis A and B vaccine"],"phase":"phase_3","status":"active","brandName":"Twinrix™ Adult","genericName":"Twinrix™ Adult","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"Twinrix is a combined vaccine that stimulates the immune system to produce antibodies against both hepatitis A and hepatitis B viruses. Used for Prevention of hepatitis A infection in adults ≥18 years, Prevention of hepatitis B infection in adults ≥18 years.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}